Clinical trial
Effectiveness of Once-weekly Exenatide (BCise) Plus Dapagliflozin on 24 Hour Glucose Variability Measured by CGM. A Proof of Concept.
NCT03970044 is registered in ClinicalTrials.gov with Consano Clinical Research, LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Effectiveness of Once-weekly Exenatide (BCise) Plus Dapagliflozin on 24 Hour Glucose Variability Measured by CGM. A Proof of Concept.
- Lead sponsor
- Consano Clinical Research, LLC
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- July 2, 2019
- Completion date
- June 1, 2021
- Enrollment
- 67 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.